Literature DB >> 3965051

The heterozygous form of 4.1(-) hereditary elliptocytosis [the 4.1(-) trait].

N Alloisio, L Morlé, E Dorléac, O Gentilhomme, D Bachir, D Guetarni, P Colonna, M Bost, Z Zouaoui, L Roda.   

Abstract

Using clinical, morphological, genetic, and biochemical criteria, we studied ten white and North African families with hereditary elliptocytosis (HE). In four families, elliptocytic individuals displayed a highly significant reduction of band 4.1, which was recorded using two electrophoretic procedures. The 4.1a/4.1b ratio was also significantly reduced, as is usually observed in suspensions enriched in young red cells. This form of HE was invariably associated with the following characteristics: absence of clinical signs; numerous, smooth and well-elongated elliptocytes; dominant transmission; and, when investigated, normal osmotic fragility. Its frequency, among all forms of HE, is about one third as a first estimate, at least in whites and North Africans. In the other six families studied, elliptocytic subjects presented normal 4.1 bands. Again, the 4.1a/4.1b ratio was decreased, reflecting the red cell age-dependent changes in these two components. In three of these families, elliptocytosis was accompanied by clinical signs of variable intensity, and the mode of inheritance could not be unequivocally determined. Therefore, HE with a partially reduced band 4.1 defines a homogeneous variety of HE that can be isolated from other forms of HE. We suggest that it be termed the 4.1 (-) trait, so as to correspond with a previously proposed terminology.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965051

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Homozygous 4.1(-) hereditary elliptocytosis associated with a point mutation in the downstream initiation codon of protein 4.1 gene.

Authors:  N Dalla Venezia; F Gilsanz; N Alloisio; M T Ducluzeau; E J Benz; J Delaunay
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Molecular analysis of insertion/deletion mutations in protein 4.1 in elliptocytosis. II. Determination of molecular genetic origins of rearrangements.

Authors:  J Conboy; S Marchesi; R Kim; P Agre; Y W Kan; N Mohandas
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Molecular analysis of insertion/deletion mutations in protein 4.1 in elliptocytosis. I. Biochemical identification of rearrangements in the spectrin/actin binding domain and functional characterizations.

Authors:  S L Marchesi; J Conboy; P Agre; J T Letsinger; V T Marchesi; D W Speicher; N Mohandas
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

4.  Protein 4.1 deficiency associated with an altered binding to the spectrin-actin complex of the red cell membrane skeleton.

Authors:  F Lorenzo; N Dalla Venezia; L Morlé; F Baklouti; N Alloisio; M T Ducluzeau; L Roda; P Lefrançois; J Delaunay
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

5.  An isoform-specific mutation in the protein 4.1 gene results in hereditary elliptocytosis and complete deficiency of protein 4.1 in erythrocytes but not in nonerythroid cells.

Authors:  J G Conboy; J A Chasis; R Winardi; G Tchernia; Y W Kan; N Mohandas
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

6.  4.1R-deficient human red blood cells have altered phosphatidylserine exposure pathways and are deficient in CD44 and CD47 glycoproteins.

Authors:  Kris P Jeremy; Zoe E Plummer; David J Head; Tracey E Madgett; Kelly L Sanders; Amanda Wallington; Jill R Storry; Florinda Gilsanz; Jean Delaunay; Neil D Avent
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.